Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

Date of Report (date of earliest event reported): September 30, 2010
 
JIANGBO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)

Florida
(State or other jurisdiction of incorporation)

333-86347
65-1130026
(Commission File Number)
(IRS Employer Identification No.)

Middle Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial Park
Laiyang City, Yantai, Shandong Province, People’s Republic of China 265200

(Address of principal executive offices and zip code)
 
(0086) 535-7282997
(Registrant's telephone number including area code)
 
 
 
(Registrant's former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
 
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o  Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
 
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 2.02      Results of Operations and Financial Condition.
 
On September 30, 2010, Jiangbo Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s operating results for the fourth quarter and fiscal year ended June 30, 2010. The Company hosted a conference call on September 30, 2010 at 9:00am Eastern time to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2010. A copy of the press release is attached hereto as Exhibit 99.1.
 
Item 9.01      Financial Statements and Exhibits.
 
Exhibit No.
Description
99.1
Press Release dated September 30, 2010.
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  JIANGBO PHARMACEUTICALS, INC.  
       
 
By:
/s/ Elsa Sung  
  Name: Elsa Sung  
  Title: Chief Financial Officer  
       
 
Dated: September 30, 2010